查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1450297

氣霧療法市場：現況分析與預測（2023-2030）

Aerosol Treatment Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

氣霧療法用於治療多種病因，包括慢性呼吸道疾病，如肺炎、慢性阻塞性肺病 (COPD) 和氣喘。根據美國疾病管制與預防中心 (CDC) 的數據：在全球範圍內，慢性阻塞性肺病、氣喘和肺炎等慢性呼吸道疾病的盛行率不斷上升，預計將推動氣霧劑治療市場的成長。

根據產品類型，市場分為乾粉吸入器、定量吸入器和霧化器。2022年，定量吸入器佔了很大的市場。定量吸入器（MDI）提供了一種方便有效的方式將藥物直接輸送到肺部，長期以來一直是呼吸醫學領域的主要產品。MDI 的持續流行和採用背後有多種驅動力。首先，它結構緊湊、便於攜帶，對於需要頻繁吸入或移動吸入的患者來說非常方便。這種移動性使您無論身在何處都可以保持用藥習慣，並促進對治療計劃的遵守。其次，計量吸入器可以達到準確且一致的劑量，確保患者每次吸入時都能收到規定量的藥物。這種精確度對於管理呼吸系統疾病和實現最佳治療結果至關重要。

根據分銷管道，市場分為醫院藥房、零售藥房、診所等。零售藥局領域在 2022 年佔據最大的收入佔有率，預計在預測期內將繼續佔據主導地位。零售藥房受到多種因素的推動，這些因素有助於其在市場上的成功和成長。首先，對醫療保健服務和藥品的需求不斷增長是主要驅動力。隨著人口持續增長和老化，對易於取得和方便找到的處方藥和非處方藥的需求日益增長。零售藥局透過提供各種藥物和保健產品來滿足這一需求，使個人可以輕鬆地在家中或工作場所附近獲得所需的藥物。

全球氣霧療法市場從地理上分為五個主要區域：北美、拉丁美洲、歐洲、亞太地區以及中東和非洲。由於慢性呼吸道疾病的高盛行率，預計北美將成為最有利可圖的氣霧治療市場。由於採用率高，預計歐洲將成為第二個利潤最高的氣霧療法市場。

由於經濟快速成長，亞太地區是一個不斷成長的氣霧療法市場，其中包括人口眾多且呼吸道疾病發病率不斷上升的中國和印度。由於氣霧劑治療呼吸道疾病的採用率較低，拉丁美洲和中東和非洲地區是氣霧劑治療市場利潤最低的地區。

市場多元化，全球和區域市場參與者眾多。

目錄

第一章 市場介紹

  • 市場定義
  • 主要目標
  • 利益相關者
  • 限制

第二章 研究方法或前提條件

  • 調查過程
  • 調查方法
  • 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章 COVID-19 對氣霧劑治療市場的影響

第六章氣霧劑治療市場收入，2020-2028

第 7 章市場洞察：依產品類型

  • 定量吸入器 (MDI)
  • 乾粉吸入器 (DPI)
  • 噴霧器

第 8 章市場洞察：依分銷管道

  • 醫院藥房
  • 零售藥店
  • 診所
  • 其他

第9章市場洞察：依地區

  • 北美
    • 美國
    • 加拿大
    • 其他北美
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 亞太其他地區
  • 世界其他地區

第10章氣霧劑治療市場動態

  • 市場驅動力
  • 市場課題
  • 影響分析

第十一章氣霧劑治療市場機會

第十二章氣霧治療市場趨勢

第十三章需求面與供給面分析

  • 需求面分析
  • 供給側分析

第十四章價值鏈分析

第15章 競爭場景

  • 競爭格局
    • 波特五力分析

第十六章公司簡介

  • Cipla Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vidal Vademecum Spain
  • Arab Drug Company
  • Socopharm Pharmaceuticals S.A.E
  • Takeda Pharmaceutical Company Limited
  • Covis Pharma GmbH
  • Hycomed
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

第十七章 免責聲明

簡介目錄
Product Code: UMHE212631

Aerosol Treatment - Aerosol is a system in which colloid ally present small solid or liquid particles are suspended in another gas. Medication is given out using aerosol in the form of mist droplets. Following inhalation, medication droplets travel from the mouth through the bronchi and alveoli. Aerosol therapy is one of the most efficient ways to treat respiratory problems because it distributes medication directly into the lower airways.

Aerosol therapy is used to treat a variety of causes, including chronic respiratory disorders like pneumonia and chronic obstructive pulmonary disease (COPD) and asthma. In accordance with the Centers for Disease Control and Prevention (CDC). Globally, the increasing prevalence of chronic respiratory conditions such as COPD, asthma, and pneumonia are expected to propel the growth of the aerosol treatment market.

Based on the product type, the market is segmented dry power inhalers, metered dose inhalers, nebulizers. The metered dose inhalers held a significant share of the market in 2022. Metered Dose Inhalers (MDIs) have long been a staple in the field of respiratory medicine, offering a convenient and effective way to deliver medication directly into the lungs. Several driving factors contribute to the continued popularity and widespread use of MDIs. Firstly, their compact and portable nature makes them incredibly convenient for patients who require frequent or on-the-go inhalations. This mobility allows individuals to maintain their medication routine regardless of their location, promoting better adherence to treatment plans. Secondly, MDIs offer precise and consistent dosing, ensuring that patients receive the prescribed amount of medication with each inhalation. This accuracy is vital in managing respiratory conditions and achieving optimal therapeutic outcomes.

Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies, clinics, and others. The Retail Pharmacies segment accounted for the largest revenue share in 2022 and is also anticipated to continue its dominance during the forecast period. Retail pharmacies are driven by several factors that contribute to their success and growth in the market. Firstly, the increasing demand for healthcare services and medications is a significant driving force. As the population continues to grow and age, the need for accessible and convenient sources of prescription drugs and over-the-counter medications rises. Retail pharmacies fulfill this need by providing a wide range of medicines and healthcare products, making it easy for individuals to access essential medications close to their homes or workplaces.

The global aerosol treatment market is divided into 5 primary geographic regions based on geography: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Due to the high prevalence of chronic respiratory diseases, North America is anticipated to be the most lucrative aerosol therapy market. Due to greater adoption rates, Europe is anticipated to be the second-most lucrative aerosol treatment market.

Because of its burgeoning economies, including China and India, which have large populations and rising rates of respiratory illnesses, Asia Pacific is a growing market for aerosol treatment. Due to the low adoption of aerosols for the treatment of respiratory disorders, Latin America and MEA are the aerosol treatment markets with the lowest profitability.

Some of the major players operating in the market include Cipla, Teva, Vidal Vademecum Spain, Arab Drug Company, Socopharm Laboratory, Takeda, Covis Pharma, Hycomed, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd. The market is diversified with a large number of global and regional market players.

TABLE OF CONTENTS

1. MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Aerosol Treatment MARKET
  • 2.2.Research Methodology of the Aerosol Treatment MARKET
  • 2.3.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE Aerosol Treatment MARKET

6. Aerosol Treatment MARKET REVENUE (USD BN), 2020-2028F

7. MARKET INSIGHTS BY PRODUCT TYPE

  • 7.1.Metered Dose Inhalers (MDIs)
  • 7.2.Dry Powder Inhalers (DPIs)
  • 7.3.Nebulizers

8. MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 8.1.Hospital Pharmacies
  • 8.2.Retail Pharmacies
  • 8.3.Clinics
  • 8.4.Others

9. MARKET INSIGHTS BY REGION

  • 9.1.North America
    • 9.1.1.U.S.
    • 9.1.2.Canada
    • 9.1.3.Rest of North America
  • 9.2.Europe
    • 9.2.1.Germany
    • 9.2.2.U.K.
    • 9.2.3.France
    • 9.2.4.Italy
    • 9.2.5.Spain
    • 9.2.6.Rest of Europe
  • 9.3.Asia-Pacific
    • 9.3.1.China
    • 9.3.2.Japan
    • 9.3.3.India
    • 9.3.4.Australia
    • 9.3.5.Rest of Asia-Pacific
  • 9.4.Rest of World

10. AEROSOL TREATMENT MARKET DYNAMICS

  • 10.1.Market Drivers
  • 10.2.Market Challenges
  • 10.3.Impact Analysis

11. AEROSOL TREATMENT MARKET OPPORTUNITIES

12. AEROSOL TREATMENT MARKET TRENDS

13. DEMAND AND SUPPLY-SIDE ANALYSIS

  • 13.1.Demand Side Analysis
  • 13.2.Supply Side Analysis

14. VALUE CHAIN ANALYSIS

15. COMPETITIVE SCENARIO

  • 15.1.Competitive Landscape
    • 15.1.1.Porters Fiver Forces Analysis

16. COMPANY PROFILED

  • 16.1.Cipla Inc.
  • 16.2.Teva Pharmaceutical Industries Ltd.
  • 16.3.Vidal Vademecum Spain
  • 16.4.Arab Drug Company
  • 16.5.Socopharm Pharmaceuticals S.A.E
  • 16.6.Takeda Pharmaceutical Company Limited
  • 16.7.Covis Pharma GmbH
  • 16.8.Hycomed
  • 16.9.Sun Pharmaceutical Industries Ltd.
  • 16.10.Aurobindo Pharma Ltd.

17. DISCLAIMER